In this study we have used the hypoxia-targeting MRI contrast agent GdDO3NI, (a nitroimidazole-based T1 contrast agent) to image the development of hypoxia in the rodent brain tumors at two different sizes. Our results indicate a range of signal enhancements from 5-20% over baseline in the 9L tumor using GdDO3NI with clearance from contralateral brain and muscle tissue. Furthermore the GdDO3NI enhancement correlates with PET imaging using hypoxia targeting 18F-FMISO and immunohistochemistry based on pimonidazole. This study further demonstrates the utility of GdDO3NI in non-invasive imaging of tissue hypoxia with high resolution.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords